Seeking Alpha 转述 Roivant brepocitinib 葡萄膜炎双 III 期阳性，同一催化已被多次处理且盘前涨近 7%

Roivant Sciences ( ROIV ) added nearly 7% in the premarket on Wednesday after the company and its subsidiary, Priovant Therapeutics, announced late-stage trial wins for the FDA-approved therapy Lisraya (brepocitinib) against an eye disorder called non-infectious uveitis. The companies added that Lisraya, an FDA-approved therapy for a rare autoimmune condition known as dermatomyositis, reached the primary and all key secondary endpoints in their CLARITY-1 and CLARITY-2 Phase 3 trials, setting the stage for a label expansion in NIU. As for the primary endpoint, they said  that brepocitinib at 45 mg was associated with more than 48 weeks in median time to treatment failure compared with roughly 12 weeks for placebo in each study. The once-daily therapy indicated a safety profile consistent with its established tolerability profile, and only 3% of subjects discontinued the treatment due to adverse events, most of which were, however, mild or moderate in severity. The companies said Priovant expects to submit a supplemental New Drug Application in H1 2027, seeking a label expansion for the oral JAK1 and TYK2 inhibitor in NIU, one of the commonest reasons for blindness in working-age people.